<DOC>
	<DOCNO>NCT01551537</DOCNO>
	<brief_summary>This PMS study aim collect safety reactogenicity data Cervarix local population per license requirement Sri Lankan regulatory authority .</brief_summary>
	<brief_title>Post-marketing Surveillance GSK Biologicals ' Cervarixâ„¢ When Administered Healthy Females Sri Lanka</brief_title>
	<detailed_description>Subjects receive one two dos Cervarix prior start PMS study also enrol study . These subject would receive either 2 dos 1 dose respectively enrol study . Since lack clarity regard PMS study requirement ( Regulatory agency Ethics Committee ) , decide GSK submit Local PSURs regular basis desire Local regulatory agency . The communicated Regulatory agency want something request revert back specific requirement .</detailed_description>
	<mesh_term>Papillomavirus Infections</mesh_term>
	<criteria>Subjects investigator believe and/or parent ( ) / LAR ( ) comply requirement protocol enrol PMS study . A female age 10 year time first vaccination . Written inform consent obtain subject . For subject legal age consent , write informed consent must obtain parent ( ) /LAR ( ) subject inform assent must obtain subject . Where subject/subject 's parent ( ) /LAR ( ) illiterate , consent form countersign impartial witness . Subjects childbearing potential must pregnant . Absence pregnancy verify per investigator 's clinical judgement . Subjects contraindication accord locally approve PI . Child care . Previous administration two dos Cervarix . Previous vaccination HPV vaccine Cervarix . Planned administration another HPV vaccine Cervarix PMS study .</criteria>
	<gender>Female</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Healthy female</keyword>
	<keyword>Post-marketing surveillance ( PMS )</keyword>
	<keyword>Human papillomavirus vaccine</keyword>
	<keyword>Sri Lanka</keyword>
	<keyword>Cervarix</keyword>
</DOC>